Metropolis rules out price hikes, guides 14–15% FY27 revenue growth
Mumbai-based diagnostics chain Metropolis Healthcare expects growth to come from 9–10% higher volumes and a richer premium wellness and specialty-test mix, not price increases. It reported Q1 revenue of ₹450 crore and targets 100–150 bps of further EBITDA-margin expansion.
Metropolis Healthcare expects 14-15% FY27 revenue growth, led primarily by patient volumes and premium wellness and specialty-test mix rather than price hikes. It targets 100-150 basis points of further EBITDA-margin expansion, while TruHealth is expected to grow about 20%.
Why this matters
The guidance follows Metropolis Healthcare's Q1 profit rising 26%, with TruHealth and Tier III markets outpacing, and signals continued reliance on mix and volume rather than pricing.
Retail-company signals are accelerating, up 166178% QoQ.